{"id":"W2136489990","doi":"10.1056/nejmoa0905561","title":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","year":2009,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":11200,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Cilag; Eisai; Sanofi; GlaxoSmithKline; Servier; Daiichi-Sankyo; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dabigatran; Medicine; Warfarin; Atrial fibrillation; Stroke (engine); Confidence interval; Anesthesia; Internal medicine; Relative risk; Direct thrombin inhibitor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}